Please ensure Javascript is enabled for purposes of website accessibility Keeping perspective on AI's role in biotech - Janus Henderson Investors
For Institutional Investors in Australia

Keeping perspective on AI’s role in biotech

Portfolio Managers Andy Acker and Agustin Mohedas say artificial intelligence (AI) has the potential to speed drug development, but ultimately, the value of the technology will have to be borne out by clinical data.

Andy Acker, CFA

Andy Acker, CFA

Portfolio Manager

Agustin Mohedas, PhD

Agustin Mohedas, PhD

Portfolio Manager | Research Analyst

Jun 15, 2023
3 minute read

Key takeaways:

  • Enthusiasm for AI has spilled into biotech, with numerous accounts of how the advanced technology will revolutionize the sector.
  • But drug development is multifaceted, and some stages of the process, such as regulatory filings and clinical testing, may see limited benefit from AI in the near term.
  • In our view, investors should keep perspective and stay focused on what matters most to the value of biotech companies: approved products backed by clinical data.

The excitement bubbling up around artificial intelligence (AI) has been spilling into the biotech sector, with a steady flow of stories about how AI is helping facilitate drug discovery – from an antibiotic that shows promise against drug-resistant bacteria to a new psoriasis treatment with multibillion-dollar sales potential. These accounts have piqued investor interest given claims that AI can speed drug development, reduce costs, and improve outcomes. In fact, a Morgan Stanley report last year estimated AI and machine learning (a subset of AI) could lead to 50 additional novel drugs worth more than $50 billion in sales over a 10-year period.1

Early signs of AI’s potential

The excitement has some merit. AI is being deployed throughout the sector and showing early signs of its potential. COVID-19 mRNA vaccines, for example, were developed in record time thanks to AI algorithms that helped design synthetic mRNA, identify drug/vaccine targets, and automate quality control steps. In breast cancer screening, AI-based 3D imaging is improving the chances of detecting invasive breast cancer earlier and reducing the number of images radiologists must review. And in a recent report, the Food and Drug Administration said it is seeing a significant increase in drug submissions with AI-based components and expects the number to accelerate from here.2

Keeping perspective

However, as with any new technology, we believe it is important for investors to remember the bottom line. While AI may appear to be accelerating medical breakthroughs, these advances are often rooted in extensive research and development, with AI playing a supporting role. Moderna, which developed one of the mRNA COVID vaccines, spent years fine-tuning synthetic mRNA and collecting and analyzing data that later could be harnessed to fight COVID. And when it comes to drug development, certain time-intensive aspects will be difficult for AI to change drastically. These include clinical development (the phase 1, 2, and 3 clinical trials that test efficacy and safety on patients) and regulatory filings and review, which together can take many years to complete.

Today, it is possible to invest in so-called digital biotech companies that use AI to develop new molecules. And while these firms are making progress in building drug pipelines, it may be many years before the companies bring a therapy to market – even as some of these stocks get lifted by AI enthusiasm.

That said, more tangible progress has been made when it comes to computational tools and methods to help enhance preclinical drug development. Today, the best biotech companies are taking advantage of these tools, benefiting the firms that provide them.

In short, we believe AI has an important future in biotech, with the potential to speed drug discovery and facilitate effective and targeted treatments for patients. But ultimately, the value of firms behind the technology will be derived from the products created – the success of which depends on clinical data that will take years to produce. Until such data are available, we believe investors should approach AI in biotech with caution.

1 Morgan Stanley, “Why Artificial Intelligence Could Speed Drug Discovery,” 9 September 2022.
2 U.S. Food and Drug Administration, “Using artificial Intelligence & Machine Learning in the Development of Drug & Biological Products,” 16 May 2023.

This information is issued by Janus Henderson Investors (Australia) Institutional Funds Management Limited (AFSL 444266, ABN 16 165 119 531). The information herein shall not in any way constitute advice or an invitation to invest. It is solely for information purposes and subject to change without notice. This information does not purport to be a comprehensive statement or description of any markets or securities referred to within. Any references to individual securities do not constitute a securities recommendation. Past performance is not indicative of future performance. The value of an investment and the income from it can fall as well as rise and you may not get back the amount originally invested.



Whilst Janus Henderson Investors (Australia) Institutional Funds Management Limited believe that the information is correct at the date of this document, no warranty or representation is given to this effect and no responsibility can be accepted by Janus Henderson Investors (Australia) Institutional Funds Management Limited to any end users for any action taken on the basis of this information. All opinions and estimates in this information are subject to change without notice and are the views of the author at the time of publication. Janus Henderson Investors (Australia) Institutional Funds Management Limited is not under any obligation to update this information to the extent that it is or becomes out of date or incorrect.